Hon CHRIS HIPKINS (Minister for COVID-19 Response): Perhaps if I could put a few things on record at this point. The first is, going back to late last year, the Government entered into advance purchaser arrangements whilst the vaccines were still in development, for four different vaccines. We purchased enough AstraZeneca vaccine, which everyone will recall at the time was seen as the most promising vaccine, the one that everyone was desperate to buy. We purchased enough for full population coverage of AstraZeneca, enough for the full two doses to be given to every New Zealander. And we purchased enough for full population coverage using the Janssen vaccine produced by Johnson & Johnson, a single shot vaccine. We procured 1.5 million doses of the Pfizer vaccine—which at that time had probably the biggest question marks over it—and we purchased 1.5 million doses, which was enough to vaccinate 750,000 New Zealanders. That quickly proved to be one of the most effective vaccines and early this year we made the decision that for New Zealand we wanted to maximise the effectiveness of the vaccines that we were rolling out, that there were benefits to rolling out one vaccine to the whole of the population.